← Back to Search

STING MARK Fiducial Marker for Cancer (StingMark Trial)

N/A
Recruiting
Led By Moishe Liberman, MD
Research Sponsored by Centre hospitalier de l'Université de Montréal (CHUM)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 1 year
Awards & highlights

StingMark Trial Summary

This trial tests a new device to accurately pinpoint the location of tumors for image-guided therapies, allowing biopsy prior to insertion.

Who is the study for?
This clinical trial is open to individuals who have received solid organ transplants or are undergoing surgical removal of solid organs. There are no specific exclusion criteria mentioned, so it appears to be broadly accessible.Check my eligibility
What is being tested?
The STING MARK Universal Fiducial Marker System is being tested for its ability to mark tumors accurately in patients with cancer. It's a new type of marker that can be delivered precisely and is visible on imaging scans, intended to improve the targeting for image-guided therapies.See study design
What are the potential side effects?
Since this trial involves a fiducial marker system rather than a drug, traditional side effects may not apply. However, potential risks could include discomfort at the insertion site or issues related to incorrect placement.

StingMark Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Gain experience with deployability of the device in multiple organs, through different needles and different routes of insertion (trans-cutaneous, endoscopic).
Medical Devices
verify radio-opacity of the device following insertion.
Secondary outcome measures
User feedback regarding usability of the device

StingMark Trial Design

1Treatment groups
Experimental Treatment
Group I: StingMark Fiducial MarkerExperimental Treatment1 Intervention
Device insertion will occur with the designated needles and through the appropriate organ-specific route and imaging guidance. Multiple STING-MARK fiducials will be inserted. Plain film x-rays in 3 planes of the organs with the marker inserted will be taken and recorded.

Find a Location

Who is running the clinical trial?

Centre hospitalier de l'Université de Montréal (CHUM)Lead Sponsor
366 Previous Clinical Trials
129,537 Total Patients Enrolled
Moishe Liberman, MDPrincipal InvestigatorCHUM
3 Previous Clinical Trials
465 Total Patients Enrolled

Media Library

StingMark Fiducial Marker Clinical Trial Eligibility Overview. Trial Name: NCT05465161 — N/A
Cancer Research Study Groups: StingMark Fiducial Marker
Cancer Clinical Trial 2023: StingMark Fiducial Marker Highlights & Side Effects. Trial Name: NCT05465161 — N/A
StingMark Fiducial Marker 2023 Treatment Timeline for Medical Study. Trial Name: NCT05465161 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any vacant slots available for participants in this medical trial?

"According to clinicaltrials.gov, this medical investigation is no longer searching for participants as the posting was last updated on February 14th 2023. Nevertheless, there are 497 other studies which are welcoming candidates at present."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
STING MARK Universal Fiducial Marker System
Moishe Liberman 2022. "STING MARK Universal Fiducial Marker System". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05465161.
~19 spots leftby Nov 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top